USPTO serial 97251008
PECSA
Reviewed by CopyMark Law Group
Status 731Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- PAYABYAB, EDWARD TAN
- Law office
- TMO LAW OFFICE 136
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with PECSA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $349*
Plus Government fees of $150
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Steven M Hoffberg
Steven M Hoffberg HOFFBERG & ASSOCIATES29 BUCKOUT ROADWEST HARRISON, NY 10604United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medicinal drinks; Medicinal herb extracts, other than essential oils; Medicinal herbal extracts for medical purposes, other than essential oils; Medicinal herbal preparations; Medicinal herbs; Medicinal herbs in dried or preserved form; Medicinal oils, other than essential oils; Medicinal tea; Anti-inflammatory preparations; Beverages containing cannabis extract, cannabigerol, cannabigerolic acid for use as a nutritional supplement; Decoctions of medicinal herb; Dietary supplement beverage for treatment of neurological diseases, seizures, inflammation, viral infection, diabetes, metabolic disorders, free radical excess; Dietary supplements also containing cannabis oil, other than essential oils; full spectrum cannabis herb extract in the nature of concentrated components of cannabis plant for medical purposes, other than essential oils; Dietary supplements consisting primarily of cannabis oil, other than essential oils; Dietary supplements for human beings; Dietary supplements for human consumption; Dietary supplements for treatment of insomnia, sleep disorders, depression, anxiety, neurodegenerative diseases, Alzheimer's disease, dementia, Parkinson's disease, post traumatic stress disorder, phobias, addictions, attention deficit hyperactivity disorder, autism, mood disorders, brain disorders, central nervous system disorders; Dietary supplements in the form of cannabis extract oil, other than essential oils, for medical purposes; Dietary and nutritional supplements containing panakeia extract in the nature of powder, oil and solution for medical purposes, other than essential oils; Dietary beverage supplements for human consumption in liquid and dry mix form for therapeutic purposes; Dietary fiber for treating constipation; Dietary fiber for use as an ingredient in the manufacture of dietary supplements; Dietary food supplements; Dietary supplements; Dietary supplements for humans; Food supplements for treatment of neurological diseases, seizures, inflammation, viral infection, diabetes, metabolic disorders, free radical excess; Health food supplements; Herb tea for medicinal purposes; Herbal extracts for medical purposes, other than essential oils; Herbal supplements; Herbal tea for medicinal purposes; Liquid herbal supplements; Liquid nutritional supplement; Medicinal roots; Natural herbal supplements; Nutraceuticals for use as a dietary supplement; Nutraceuticals for use as a dietary supplement for treatment of insomnia, sleep disorders, depression, anxiety, neurodegenerative diseases, Alzheimer's disease, dementia, Parkinson's disease, post traumatic stress disorder, phobias, addictions, attention deficit hyperactivity disorder, autism, mood disorders, brain disorders, central nervous system disorders; nutritional supplements for the treatment of neurological diseases, seizures, inflammation, viral infection, diabetes, metabolic disorders, free radical excess; Nutritional supplements; Nutritional supplements consisting primarily of cannabis oil, other than essential oils; Nutritional supplements for treatment of neurological diseases, seizures, inflammation, viral infection, diabetes, metabolic disorders, free radical excess; Nutritional supplements for treatment of insomnia, sleep disorders, depression, anxiety, neurodegenerative diseases, Alzheimer's disease, dementia, Parkinson's disease, post traumatic stress disorder, phobias, addictions, attention deficit hyperactivity disorder, autism, mood disorders, brain disorders, central nervous system disorders; Nutritional supplements in the form of oil other than essential oils, ground seeds, capsules, gelcaps; Nutritional food additives for medical purposes in the nature of natural food extracts derived from cannabis; Plant and herb extracts for medicinal purposes, other than essential oils; Plant and herb extracts for medicinal purposes, other than essential oils, sold as components of medicated cosmetics; Plant extracts for medical, veterinary and pharmaceutical purposes, other than essential oils; Plant extracts for pharmaceutical purposes, other than essential oils; all of the foregoing cannabis-related goods containing cannabis ingredients solely derived from hemp with a delta-9-tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis and containing no CBD | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 5, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 5, 2026 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Nov 4, 2026 | EXT2 | SOU EXTENSION 2 FILED | — |
| Nov 4, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 5, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 5, 2026 | EX1G | SOU EXTENSION 1 GRANTED | — |
| May 4, 2026 | EXT1 | SOU EXTENSION 1 FILED | — |
| May 4, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 4, 2025 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Sep 9, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 9, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 3, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 8, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 8, 2025 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 8, 2025 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Aug 8, 2025 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Aug 8, 2025 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Nov 15, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 14, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 14, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 14, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 14, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 14, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 17, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 8, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 5, 2022 | NWAP | NEW APPLICATION ENTERED | — |